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Herein, we report that dihydrolipoic acid and lipoic acid (LA) plus lipoamide dehydrogenase and
NADH denitrosate S-nitrosocaspase 3 (CASP-SNO). In HepG2 cells, S-nitroso-L-cysteine ethyl ester
(SNCEE) impeded the activity of caspase 3 (CASP-SH), while a subsequent incubation of the cells
in SNCEE-free medium resulted in endogenous denitrosation and reactivation of CASP-SH. The latter
process was inhibited in thioredoxin reductase-deﬁcient HepG2 cells, in which, however, LA mark-
edly reactivated CASP-SH. The data obtained are discussed with focus on low molecular mass dithi-
ols that mimic the activity of thioredoxin in reactions of protein S-denitrosation.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Caspases are a family of cysteine proteases that play an essen-
tial role in the signaling cascade leading to apoptosis. Apoptosis,
or programmed cell death, is distinguished from lytic or necrotic
cell death by a number of biochemical and structural events. Apo-
genic signals trigger speciﬁc signaling pathways, including activa-
tion of proteases, which are followed by the appearance of speciﬁc
morphologic changes such as condensation of nuclei and cyto-
plasm, blebbing of cytoplasmic membranes, and ﬁnally fragmenta-
tion into apoptotic bodies that are phagocytosed by neighboring
cells [1]. Apoptosis is important to physiologic processes such as
cell selection in development and immunologic responses [2], con-
trol of organ size in maturation and regeneration [3], and normal
cell turnover throughout the organism [4]. Dysregulated apoptosis
may contribute to pathologic states such as autoimmune disease
[5] and malignancy [6]. Upon exposure to a proapoptotic signal,chemical Societies. Published by E
E, S-nitroso-L-cysteine ethyl
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).zymogen forms of caspases constitutively present in cells are pro-
teolytically cleaved and activated. Initiator caspases such as cas-
pase 8, 9, and 10 can cleave other caspases, while executioner
caspases, including caspase 3 (CASP-SH), 6, and 7, cleave death
substrates [7].
Nitric oxide (NO), produced either extracellularly by lowmolec-
ular mass (LMM) compounds or intracellularly by nitric oxide
synthases, impedes CASP-SH activity via reactions of S-nitrosation
[8–10]. CASP-SH can undergo poly-S-nitrosation, whereby all SNO
functions in its p12 subunit are denitrosated by reduced glutathi-
one (GSH) except for a single SNO group [9]. Since the latter was
not observed in a mutant form of CASP-SH lacking the active site
cysteine, Zech et al. proposed that in cells NO nitrosates this cys-
teine to form S-nitrosocaspase 3 (CASP-SNO) that is resistant to
reduction by GSH [9]. However, denitrosation of CASP-SNO back
to CASP-SH with reconstitution of its proteolytic activity is cata-
lyzed in cellular cytosol by human thioredoxin type 1 (Trxn;
[11,12]; Scheme 1). In mitochondria, thioredoxin type 2 has been
found to mediate denitrosation of mitochondria-associated CASP-
SH, a process required for caspase 3 activation [13]. Trxn contains
a -Cys-Gly-Pro-Cys- motif that is essential for its enzyme activity.
Cysteines 32 and 35 in the active site of Trxn(SH)2 can reduce
SNO functions in substrate proteins with concomitant disulﬁde
ring closure to Trxn(S)2 and release of nitroxyl (HNO; [12,14,15]).
In turn, Trxn(S)2 is converted back to Trxn(SH)2 by the NADPH-













3526 R. Sengupta et al. / FEBS Letters 583 (2009) 3525–3530Sustained production of endogenous NO has been shown to de-
crease both the expression and the activities of Trxn and TrxnR
[17–19]. This suggests that shifts in the rates of S-nitrosation and
denitrosation of CASP-SH following changes in either NO produc-
tion or activity of the Trxn/TrxnR/NADPH system will modulate
CASP-SH-dependent apoptotic pathways. Within the scope of this
mechanism, we were interested to verify whether LMM dithiols
can mimic the activity of Trxn toward CASP-SNO. To this end, we
have focused on dihydrolipoic acid (DHLA; 6,8-dimercaptooctanoic
acid), which is the reduced form of lipoic acid (LA; 5-[1,2]dithiolan-
3-yl-pentanoic acid), a cyclic disulﬁde that is an essential pros-
thetic group in the dihydrolipoyl transacetylase component of
the a-ketoacid dehydrogenase complex in mitochondria. In cells,
LA (Scheme 2, 1) is reduced to DHLA (2) by lipoamide dehydroge-
nase (LD) with consumption of NADH; in addition, reduction of LA
to DHLA is catalyzed by NADPH-dependent reductases (including
TrxnR; [20,21]). Herein, we present experimental evidence that
DHLA fully denitrosates CASP-SNO in chemical systems and regen-
erates the activity of CASP-SH in TrxnR-deﬁcient HepG2 cells ex-
posed to NO.
2. Materials and Methods
2.1. Reagents
All reagents and human recombinant C-terminal histidine
tagged caspase 3 were purchased from Sigma Chemical Co. (St.
Louis, MO). The solutions used in the experiments were prepared
in deionized and Chelex-100-treated water or potassium phos-
phate buffer.
2.2. Preparation of S-nitroso-L-cysteine ethyl ester (SNCEE)
S-Nitrosation of the ethyl ester of cysteine (HS-Cys-OEt) was
carried out with nitrosooxy ethane (C2H5ONO) as described previ-











Scheme(5 ml) containing C2H5ONO (0.5 ml; b.p. 13 C) and the reaction
solutions was incubated for 30 min in ice. Thereafter, the solvent
and the remaining C2H5ONO were rotor-evaporated (2 mm Hg) at
room temperature and the nitrosothiol formed was re-crystallized
from methanol. The purity of the nitrosothiols was assessed by UV
spectrophotometry (in methanol, e(343)SNCEE = 1019 M1 cm1 and
e(544)SNCEE = 36 M1 cm1 [22]. During the preparation of SNCEE,
care must be exercised in handling solutions containing C2H5ONO,
as inhalation of its vapor may cause severe headache and heart
excitation. The preparation must therefore be conducted in an efﬁ-
cient fume cupboard.
2.3. Preparation of CASP-SNO
S-nitrosation of CASP-SH (3 lM) was performed with S-nitroso-
glutathione (GSNO) (0.3 mM) at 20 C for 30 min in 0.1 M phos-
phate buffer containing 0.2 mM EDTA. Thereafter, CASP-SNO was
separated from GSH and the excess of GSNO via ultraﬁltration
(3 kDa Vivaspin cut-off ﬁlter; 30 min at 12 000g), which included
four washing cycles with 0.2 ml of the reaction buffer.
2.4. Analysis of CASP-SNO
CASP-SNO was quantiﬁed following its Cu+-catalyzed break-
down to CASP-SH and NO with concomitant chemiluminescence
measurements of the latter in the gas-phase using a Sievers Nitric
Oxide analyzer (NOATM 280i; Boulder, CO) [11]. The purge vessel of
the NO analyzer was ﬁlled with 5 ml of 0.1 M phosphate buffer (pH
7.4; 20 C; gas carrier, He). In the reaction vessel, a steady-state
concentration of Cu+ was maintained by a large excess of ascorbic
acid over CuCl2 (50 mM vs. 0.2 mM). Thus, multiple injections of
aliquots (5 ll) containing CASP-SNO could be made without any
signiﬁcant loss of analytical sensitivity. Under these experimental
conditions, NaNO2 (up to 0.1 mM) does not interfere with the anal-
ysis of CASP-SNO [11].
2.5. CASP-SH assay
In cell lysates, CASP-SH activity was measured ﬂuorometrically
on a LS50B Perkin–Elmer spectroﬂuorimeter (kex = 380 nm; kem =
420 nm; excitation/emission slit, 5 nm) using 0.15 mM Asp-Glu-
Val-Asp-7-amido-4-methyl-coumarin as a substrate (Sigma Inc.,
St. Louis, MO).2.6. Cell culture and treatments
Human hepatoma (HepG2) cells were cultured in the Dul-
becco’s modiﬁed Eagle’s medium supplemented with 10% fetal calf
serum, 100 U/ml penicillin, 100 lg/ml streptomycin, and 2 mM L-
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were grown in T75 ﬂasks for 24 h and then incubated for 4.5 h with
medium (control) or with medium containing TNF-a (15 nM) and
cycloheximide (40 lM; Sigma; St. Louis, MO; [23]).Thereafter, the
cells were washed with PBS (3  10 ml) and incubated for 15 min
at 37 C with standard incubation medium containing SNCEE.
Whole-cell lysates for analysis of CASP-SH were harvested by
repeated freeze and thaw cycles followed by centrifugation at
15 000g for 15 min at 4 C.
2.7. siRNA transfection
The siRNA directed against TrxnR was 50-AGACCACG UUA-
CUUGG GCAdTdT-30 and the control was a scrambled sequence
(50-AGGCAAAUCACGGUGUCCUdTdT-30) that does not match any
sequence in the GenBank human database for >16 nt ([24]; Dharm-
acon RNA Technologies; Chicago, IL). Approximately 2  105
HepG2 cells were plated per well in a six-well plate. The following
day, siRNA were transfected with lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA), with 30 pmol siRNA per well [25], according
to the manufacturer’s recommendations. Transfection with the
same amount of non-speciﬁc siRNA was performed as control.
The cells were harvested and analyzed at 24, 48, and 72 h after
transfection for cell viability, activity, and level of TrxnR protein.
2.8. Western blots
Cells were disrupted by three consecutive freeze and thaw cy-
cles and then centrifuged at 15 000g for 15 min at 4 C to remove
membrane fractions. Equal amounts of protein (20–30 lg) were re-
solved by SDS–PAGE (10%) and transferred on to a nitrocellulose
membrane. The membrane was blocked in 5% (w/v) dried milk
powder in TBS (Tris-buffered saline) with (v/v) 0.01% Tween-20
at room temperature and was incubated with anti-TrxR1 (Rabbit
IgG, Upstate) (1:500 dilution) overnight in 5% (w/v) BSA in TBS
with 0.01% (v/v) Tween-20. Secondary antibody (HRP-conjugated
anti-rabbit IgG; 1:1000 dilution; Pierce; Rockford, IL) was then
added to the membrane for 1 h at room temperature, washed,
and thereafter the membrane was exposed to HRP substrate
(Pierce SuperSignal West Pico Chemiluminescent Substrate) and
visualized by chemiluminescence on autoradiography ﬁlm.
2.9. TrxnR assay
TrxnR activity was determined in a coupled assay with Esche-
richia coli Trxn (10 lM) and 5,50-dithiobis(2-nitrobenzoic acid)
(DTNB) as described in Ref. [11]. One unit of TrxnR activity was de-
ﬁned as the formation of 74 lmol of 5-mercapto-2-nitro-benzoic
acid (1 absorbance unit at 412 nm; e412 = 13 500 M1 cm1) per
min per ml at pH 7.0 at 25 C.Fig. 1. DHLA denitrosates CASP-SNO. Reactions were carried out at 25 C in 0.1 M
phosphate buffer (pH 7.4) containing 0.1 mM EDTA. CASP-SNO, DHLA, NADH, and
LA were used at concentrations of 0.8, 50, 400, and 50 lM, respectively; LD, 1 unit/
ml. At given time points (arrows), aliquots from the reaction solutions were
assessed for CASP-SNO content as described in Section 2. Trace (a) CASP-SNO and
LA; (b) CASP-SNO and DHLA; (c) CASP-SNO, LD and NADH; (d) CASP-SNO, LA, LD,
and NADH. Results are representative of three independent experiments.2.10. Data analysis
Results are given as mean ± S.E. (n = 3–6).
3. Results and discussion
3.1. S-Denitrosation of CASP-SNO by DHLA
LMM compounds containing vicinal dithiols such as threo-1,4-
dimercapto-2,3-butanediol (Cleland’s reagent; DTT) and DHLA re-
act with RSNO to form RSH and disulﬁdes with generation of
HNO, NH3, NH2OH, and NO. In this reaction, the ratio between
end products depends on the presence of nitrate anion and the de-
gree of S-nitrosation of the parent dithiols. Mono-S-nitroso thiolstend to release HNO [12,14,26], whereas di-S-nitrosothiols under-
go cyclization to disulﬁdes with release of NO [14,27].
At mM concentrations, DTT and both LA and DHLA have been
shown to cause toxicity via induction of reductive stress [28] and
activation of CASP-SH, respectively ([29] and the references there-
in). However, pharmacological experiments are often carried out
with 10 mg of LA per kg of body weight [30,31], whereas therapeu-
tic results in humans are achieved at plasma concentrations of 10–
20 lg/ml (50–100 lM) LA [31,32]. Hence, we were interested to
verify whether CASP-SNO can be denitrosated by pharmacological
concentrations DHLA (Scheme 2).
Puriﬁed CASP-SNO, which contains 5 SNO functions per mol of
protein [12], exhibited insigniﬁcant proteolytic activity and did not
decompose to any signiﬁcant extent in the presence of LA or LD
plus NADH (Fig. 1a and c). However, both DHLA and the complete
3528 R. Sengupta et al. / FEBS Letters 583 (2009) 3525–3530LA/LD/NADH system denitrosated CASP-SNO (Fig. 1b and d) with
concomitant reconstitution of the enzyme activity of CASP-SH
(Fig. 2). Notably, CASP-SNOwas fully denitrosated by DHLA. In con-
trast to LA, a series of LMM disulﬁdes have been shown to inhibit
CASP-SH via formation of protein mixed disulﬁdes [33,34].
To assess the potential of DHLA to denitrosate CASP-SNO in in-
tact cells, we have conducted experiments with control and TrxnR-
deﬁcient HepG2 cells. In cells, TrxnR was silenced using siRNA,
while release of CASP-SH in the cellular cytosol was attained with
TNF-a and cycloheximide [11]. In contrast to hepatocytes, HepG2
cells are deﬁcient in some phase I enzymes [35–37], including alco-
hol dehydrogenase class III (ADH; also referenced as GSNO reduc-
tase), which catalyzes the denitrosation of GSNO [38]. Hence,
control and TrxnR-deﬁcient HepG2 cells offered the advantage to
study Trxn-catalyzed reactions of S-denitrosation without interfer-
ence of ADH.
Incubation of HepG2 cells for 72 h with siRNA (30 nM) caused a
50% decrease in the activity of TrxnR (Fig. 3A) without affectingFig. 2. S-Denitrosation of CASP-SNO by DHLA leads to reconstitution of the
proteolytic activity of CASP-SH. Reactions were carried out as indicated in Fig. 1.
At given time points (0 min (d), 10 min (s), and 20 min (h)), aliquots from the
reaction solution consisting of CASP-SNO and DHLA were assessed for CASP-SH
activity. Data are presented as mean values of three independent experiments ± S.E.
Fig. 3. Inhibition of TrxnR and activation of caspase 3 in HepG2 cells. Experiments aime
carried out as described in Section 2. (A) Inset – Western analysis of cells transfected wit
(lane 3). (B) Activity of caspase 3 in HepG2 cells exposed to TNF-a (5 nM, triangles; 15 nM
the means ± S.E. (n = 3).the levels of intracellular GSH to any signiﬁcant extent (data not
shown). Western blot analysis established that, in siRNA-treated
cells, the protein levels of TrxnR had markedly decreased
(Fig. 3A, inset). For S-nitrosation of thiols, cells were incubated
with SNCEE, which readily crosses cell membranes and trans-S-
nitrosates intracellular proteins [11,12,22]. While at concentra-
tions of 0.20.8 mM SNCEE impedes the activity of TrxnR and
causes toxicity in HepG2 cells [11], experiments aimed to assess
the nitrosative inactivation of CASP-SH were carried out with
50 lM SNCEE.
Exposure of HepG2 cells to cycloheximide and TNF-a resulted in
a dose- and time-dependent activation of CASP-SH, whereby max-
imal activity of the protease was attained after and incubation for
4.5 h with 15 nM TNF-a (Fig. 3B). Thereafter, control and TrxnR-
deﬁcient HepG2 cells were incubated for 15 min with 50 lM
SNCEE. The cells were then washed with PBS and the activity of
CASP-SH was assessed either immediately (time for preparation
of reaction solutions for spectral analysis, 5 min) or after an addi-
tional incubation for 60 min at 37 C in SNCEE-free incubation
medium.
The rationale for this experimental design was based on previ-
ously established kinetics of denitrosation of CASP-SNO by the
Trxn/TrxnR/NADPH system [11], with the hypothesis that time-
dependent increases in CASP-SH activity would reﬂect the rates
of endogenous reactions of S-denitrosation. Treatment of control
HepG2 cells with SNCEE led to 80% (5 min) and 5% (60 min in
SNCEE-free incubation medium) inhibition of CASP-SH (Fig. 4A).
The regeneration of CASP-SH activity was insigniﬁcant in TrxnR-
deﬁcient cells (Fig. 4B), which suggests the requirement for Trxn
catalysis in this process. However, substitution of SNCEE with LA
followed by incubation for 60 min led to a marked reactivation of
CASP-SH activity in TrxnR-deﬁcient HepG2 cells (Fig. 4B), presum-
ably via intracellular reduction of LA to DHLA and reaction of the
latter with CASP-SNO. Notably, CASP-SH activity was reconstituted
more efﬁciently by 50 lM LA than by 5 mM DTT (Fig. 4B). In this
set of experiments, qualitatively the same effects were observed
when SNCEE was substituted for S-nitroso-N-acetyl-DL-penicilla-
mine (SNAP; incubation time, 1 h; data not shown).
The data presented herein provide a proof of concept that LMM
dithiols can mimic the activity of Trxn in reactions of protein S-
denitrosation. Several disease states have been associated withd to silence TrxnR in HepG2 cells with siRNA (A) and to activate caspase 3 (B) were
h scrambled siRNA (lane 1), untransfected cells (lane 2), and siRNA-transfected cells
, circles) and cycloheximide (40 lM); no addition, rectangles. The results represent
Fig. 4. SNCEE and LA modulate CASP-SH activity in HepG2 cells. CASP-SH activity was stimulated with TNF-alpha (15 nM) plus cycloheximide (40 lM) as described in Section
2; then, the cells were incubated for 15 min at 37 C with SNCEE (50 lM), washed with PBS, and assayed for CASP-SH activity either immediately or after an additional
incubation for 60 min with SNCEE-free incubation medium in the absence and in the presence of LA (50 lM) or DTT (5 mM). Control activity of TrxnR, 0.12 units/mg protein
(Panel A); in lysates of (TNF-a plus cycloheximide)-treated HepG2 cells, 7-amino-4-methylcoumarin was generated at a rate of 2.8 nmol/min/mg protein/ml. The results
represent the means ± S.E. (n = 3).
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homeostasis of Trxn. Examples of such diseases are liver steatosis
and cirrhosis [39–41], rheumatoid arthritis [42–45], bronchopul-
monary dysplasia [46–48], and asthma [49,50]. Hence, DHLA and
structurally similar LMM disulﬁdes/dithiols could be instrumental
in assessments of the involvement and speciﬁc roles of reactions of
S-nitrosation. It could be further hypothesized that denitrosation of
S-nitrosothiols by LMM dithiols may be used to counteract the tox-
icity of NO and drugs that act as S-nitrosating agents, such as glyc-
eryl trinitrate, nitrosooxyethane, and nitrosoaspirine [22,51–53].
This is an experimentally veriﬁable hypothesis for which support
has not previously been generated. Hence, further studies are
needed to assess the structure/activity relationship of the reduc-
tion of LMM disulﬁdes to dithiols by NADH- and NADPH-depen-
dent reductases, as well as to deﬁne the factors that affect the
rates of protein S-denitrosation by LMM dithiols.Acknowledgments
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